Sangyeul Han

President
Chief Executive Officer

Sangyeul Han founded Ingenia Therapeutics in 2018. Previously, he worked at Cell Signaling Technology where he led its Antibody Technology and Molecular Biology groups. Before CST, he worked for the Institute for Basic Science as a research fellow investigating vascular biology and Samsung Advanced Institute of Technology, where he led a project for the development of therapeutic antibodies for multiple diseases. He finished his post-doctoral training at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) where he studied the pathological mechanisms of several tumor suppressor syndromes. He also worked as an instructor at MGH/HMS. He has authored over 20 publications in scientific journals and holds multiple patents in the areas of therapeutic antibody development. 

Sangyeul holds B.S., M.S., and Ph.D. degrees from Seoul National University, South Korea where his graduate research focused on investigating the regulatory mechanism of secretory protein trafficking in mammalian cells.

Mahesh Lachyankar

Senior Vice President
Chief Business Officer

Mahesh Lachyankar, Ph.D. joined Ingenia Therapeutics in April 2021. Before joining Ingenia, Mahesh worked for several early and mid-stage biotech companies including those founded by VCs like Atlas Ventures, DDF, and SV Life. During this period, Mahesh developed strategies for the pursuit of the company’s science and business goals; resulting in enabling fundraises or successful planned exits. Mahesh served as Chief Scientific Advisor to USAMRIID and developed their internal and external research programs. Mahesh was Director and site lead for Pfizer Inc. and before that, worked at Abbott Labs (now AbbVie Inc).

Mahesh obtained his Ph.D. from Bombay University and did post-doctoral training at Harvard University.

Theresa O’Keefe

Senior Vice President
Chief Scientific Officer

Theresa O’Keefe joined Ingenia Therapeutics in 2022. Previously she had her own consulting firm, Silladar Consulting LLC, where she assisted multiple small companies, including Elicio Therapeutics, ONEighty C Technologies and Premas Biotech, develop their biotherapeutics and medical devices. Over the years she has worked for a number of biopharma and pharmaceutical companies including Pfizer, Critical Therapeutics and Millennium/Takeda where she created and led multiple antibody development groups and programs. During her time at Millennium, she invented nLDP02 that went on to be approved as Entyvio, Takeda’s antibody for Crohn’s and UC, as well as its high expression manufacturing system. Her postdoctoral training and early academic career were spent at the MRC-Laboratory of Molecular Biology, Cambridge, UK, where she trained under Michael Neuberger and Caesar Milstein. Theresa currently teaches a class in biotherapeutic drug development at UMASS Medical School and is an inventor on over 30 issued patents and has 15 publications including multiple Tier 1 publications.

Theresa obtained an A.B. cum laude in Biochemistry and Biological Sciences from Mount Holyoke College, a M.S. in Veterinary Physiology from Purdue University and a Ph.D. in Immunology from Tufts University’s Graduate School of Biomedical Sciences.

Peter Park

Vice President
Chief Financial Officer

Peter Park joined Ingenia Therapeutics in 2020. Before joining Ingenia, Peter worked at Genosco Inc. where he was Director and Treasurer.  Prior to Genosco, Peter worked at Acushnet Company for 7+ years and held financial planning and investor relations positions. In those roles at Acushnet, Peter was the lead contact for private equity investors in South Korea and was instrumental in bringing the company to a successful IPO at NYSE in 2016.  Peter also spent time earlier in his career working for a venture capital firm and a family office as an accounting & tax manager. 

Peter is a Certified Public Accountant and holds an M.S.A. from the University of Illinois and a B.A. in Russian Language & Literature from Korea University.

Jinsam You

Vice President
Preclinical Development

Jinsam You joined Ingenia Therapeutics in 2022. Previously, he worked at Eli Lilly and company where he led the early stage of drug development programs. He made numerous contributions on immunogenicity risk assessment, antibody engineering, and biomarker strategy. Prior to his tenure with Eli Lilly, he served as a lecturer and scientific director at the Indiana university school of medicine. He also worked at a protein research startup called Monarch Life Sciences LLC where he led a biomarker discovery and assay development group.

Jinsam obtained his Ph.D. degree in biochemistry and molecular biology from Pusan National University, South Korea and did post-doctoral training at Indiana university school of medicine.

Jaewoo Shim

Vice President
IR & Corporate Development

Jaewoo Shim joined Ingenia Therapeutics in 2020. Jaewoo is an expert in the areas of Investor Relations and Public Relations.  Jaewoo brings over 25 years of media experience in TV and Newspapers, especially the Economy and Biotechnology Industry Desk.  Jaewoo was a recipient of the GlaxoSmithKline Science Journalist Award in 2008. Jaewoo is also an author of the book ‘New Drug Odyssey (2008).

Jaewoo holds an M.B.A from KAIST College of Business in Seoul, South Korea.  He earned his B.S. and M.S. in Molecular Biology from Seoul National University.